BIT
CLDX icon

BlackRock Institutional Trust’s Celldex Therapeutics CLDX Stock Holding History

BlackRock Institutional Trust’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$9.7M Buy
182,665
+22,959
+14% +$1.31M ﹤0.01% 2420
2016
Q3 		$9.68M Buy
159,706
+1,516
+1% +$94.4K ﹤0.01% 2351
2016
Q2 		$10.4M Sell
158,190
-375
-0.2% -$23.8K ﹤0.01% 2268
2016
Q1 		$8.99M Sell
158,565
-1,948
-1% -$219K ﹤0.01% 2329
2015
Q4 		$37.8M Buy
160,513
+6,950
+5% +$1.52M 0.01% 1435
2015
Q3 		$24.3M Sell
153,563
-853
-0.6% -$241K ﹤0.01% 1699
2015
Q2 		$58.4M Sell
154,416
-44,940
-23% -$17.8M 0.01% 1209
2015
Q1 		$83.3M Buy
199,356
+47,602
+31% +$17M 0.01% 1029
2014
Q4 		$41.5M Sell
151,754
-8,821
-5% -$2.19M 0.01% 1412
2014
Q3 		$31.2M Sell
160,575
-4,354
-3% -$949K 0.01% 1589
2014
Q2 		$40.4M Buy
164,929
+986
+0.6% +$223K 0.01% 1464
2014
Q1 		$43.5M Buy
163,943
+4,781
+3% +$1.83M 0.01% 1389
2013
Q4 		$57.8M Buy
159,162
+12,681
+9% +$4.89M 0.01% 1166
2013
Q3 		$77.8M Sell
146,481
-4,641
-3% -$1.59M 0.02% 931
2013
Q2 		$35.4M Buy
+151,122
New +$29.8M 0.01% 1375

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

BlackRock Institutional Trust's CLDX Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Celldex Therapeutics (CLDX) stake by 14% in Q4 2016, buying an estimated $1.31M and bringing the position to 182,665 shares worth $9.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2420.

BlackRock Institutional Trust first reported a position in CLDX in Q2 2013 and has held it in 15 quarters since. The position peaked at $83.3M in Q1 2015. 140 funds tracked by Wall St. Rank hold CLDX as of Q4 2016.

  • BlackRock Institutional Trust held 182,665 shares of Celldex Therapeutics worth $9.7M as of Q4 2016.
  • BlackRock Institutional Trust bought 22,959 Celldex Therapeutics shares in Q4 2016, an estimated $1.31M.
  • Celldex Therapeutics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2420 holding.
  • BlackRock Institutional Trust first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Institutional Trust's Celldex Therapeutics position peaked at $83.3M in Q1 2015.
  • 140 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.